206 related articles for article (PubMed ID: 30981875)
21. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man.
Venkatakrishnan K; von Moltke LL; Duan SX; Fleishaker JC; Shader RI; Greenblatt DJ
J Pharm Pharmacol; 1998 Mar; 50(3):265-74. PubMed ID: 9600717
[TBL] [Abstract][Full Text] [Related]
22. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
Bakken GV; Molden E; Knutsen K; Lunder N; Hermann M
Drug Metab Dispos; 2012 Sep; 40(9):1778-84. PubMed ID: 22688609
[TBL] [Abstract][Full Text] [Related]
23. Metabolic characterization of (1-(5-fluoropentyl)-1H-indol-3-yl)(4-methyl-1-naphthalenyl)-methanone (MAM-2201) using human liver microsomes and cDNA-overexpressed cytochrome P450 enzymes.
Kong TY; Kim JH; Choi WG; Lee JY; Kim HS; Kim JY; In MK; Lee HS
Anal Bioanal Chem; 2017 Feb; 409(6):1667-1680. PubMed ID: 27924364
[TBL] [Abstract][Full Text] [Related]
24. Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome.
Meyers NL; Hickling RI
Drugs R D; 2008; 9(1):37-63. PubMed ID: 18095752
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of cytochrome P450 enzymes involved in ketamine metabolism by use of liver microsomes and specific cytochrome P450 enzymes from horses, dogs, and humans.
Mössner LD; Schmitz A; Theurillat R; Thormann W; Mevissen M
Am J Vet Res; 2011 Nov; 72(11):1505-13. PubMed ID: 22023129
[TBL] [Abstract][Full Text] [Related]
26. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K
Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
[TBL] [Abstract][Full Text] [Related]
27. Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes.
Dalmadi B; Leibinger J; Szeberényi S; Borbás T; Farkas S; Szombathelyi Z; Tihanyi K
Drug Metab Dispos; 2003 May; 31(5):631-6. PubMed ID: 12695352
[TBL] [Abstract][Full Text] [Related]
28. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions.
Labroo RB; Paine MF; Thummel KE; Kharasch ED
Drug Metab Dispos; 1997 Sep; 25(9):1072-80. PubMed ID: 9311623
[TBL] [Abstract][Full Text] [Related]
29. Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP). In vivo studies in Wistar and Dark Agouti rats as well as in vitro studies in human liver microsomes.
Staack RF; Paul LD; Springer D; Kraemer T; Maurer HH
Biochem Pharmacol; 2004 Jan; 67(2):235-44. PubMed ID: 14698036
[TBL] [Abstract][Full Text] [Related]
30. Biotransformation of 6-methoxy-3-(3',4',5'-trimethoxy-benzoyl)-1H-indole (BPR0L075), a novel antimicrotubule agent, by mouse, rat, dog, and human liver microsomes.
Yao HT; Wu YS; Chang YW; Hsieh HP; Chen WC; Lan SJ; Chen CT; Chao YS; Chang L; Sun HY; Yeh TK
Drug Metab Dispos; 2007 Jul; 35(7):1042-9. PubMed ID: 17403915
[TBL] [Abstract][Full Text] [Related]
31. Enzymic formation of dehydrogenated and hydroxylated metabolites from lysergic acid diethylamide by rat liver microsomes.
Inoue T; Niwaguchi T; Murata T
Xenobiotica; 1980 May; 10(5):343-8. PubMed ID: 7415216
[TBL] [Abstract][Full Text] [Related]
32. Involvement of CYP3A4/5 and CYP2D6 in the metabolism of aconitine using human liver microsomes and recombinant CYP450 enzymes.
Tang L; Ye L; Lv C; Zheng Z; Gong Y; Liu Z
Toxicol Lett; 2011 Apr; 202(1):47-54. PubMed ID: 21277363
[TBL] [Abstract][Full Text] [Related]
33. In vitro effects of tacrolimus on human cytochrome P450.
Lecointre K; Furlan V; Taburet AM
Fundam Clin Pharmacol; 2002 Dec; 16(6):455-60. PubMed ID: 12685503
[TBL] [Abstract][Full Text] [Related]
34. Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs).
Rickli A; Luethi D; Reinisch J; Buchy D; Hoener MC; Liechti ME
Neuropharmacology; 2015 Dec; 99():546-53. PubMed ID: 26318099
[TBL] [Abstract][Full Text] [Related]
35. d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology.
De Gregorio D; Comai S; Posa L; Gobbi G
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27886063
[TBL] [Abstract][Full Text] [Related]
36. Hyperthermic effects of D-lysergic acid diethylamide (LSD) and its derivatives in rabbits and rats.
Hashimoto H; Hayashi M; Nakahara Y; Niwaguchi T; Ishii H
Arch Int Pharmacodyn Ther; 1977 Aug; 228(2):314-21. PubMed ID: 303504
[TBL] [Abstract][Full Text] [Related]
37. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone.
Baldwin SJ; Clarke SE; Chenery RJ
Br J Clin Pharmacol; 1999 Sep; 48(3):424-32. PubMed ID: 10510156
[TBL] [Abstract][Full Text] [Related]
38. In vitro characterization of 4'-(p-toluenesulfonylamide)-4-hydroxychalcone using human liver microsomes and recombinant cytochrome P450s.
Lee B; Wu Z; Lee T; Tan XF; Park KH; Liu KH
Xenobiotica; 2016; 46(4):350-6. PubMed ID: 26330107
[TBL] [Abstract][Full Text] [Related]
39. In vitro metabolism of zolmitriptan in rat cytochromes induced with beta-naphthoflavone and the interaction between six drugs and zolmitriptan.
Yu LS; Yao TW; Zeng S
Chem Biol Interact; 2003 Dec; 146(3):263-72. PubMed ID: 14642738
[TBL] [Abstract][Full Text] [Related]
40. Detection of metabolites of lysergic acid diethylamide (LSD) in human urine specimens: 2-oxo-3-hydroxy-LSD, a prevalent metabolite of LSD.
Poch GK; Klette KL; Hallare DA; Manglicmot MG; Czarny RJ; McWhorter LK; Anderson CJ
J Chromatogr B Biomed Sci Appl; 1999 Mar; 724(1):23-33. PubMed ID: 10202954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
